MAP2K1 and metastatic melanoma: Since various PLK1 inhibitors are already being assessed individually in clinical trials and MEK1/2 inhibitor trametinib is recently approved by FDA for treating patients with metastatic melanoma, our data suggest that a combination strategy could have better efficacy in basal‐like, TNBCs that exhibit highly aberrant copy‐number profile.